MEASUREMENT OF PULMONARY ARTERY & RIGHT HEART PRESSURES

对各种心脏和肺部疾病的管理是非常重要的。 由于缺乏定量的压力和流量数据，这一点很难实现。可靠 右心压不可能是非侵入性的。从长远来看 拟议活动的目的是专门针对非侵入性的 测量右心压。为了做到这一点，微小的微泡 将在进入区域时进行超声波注射和辐射 需要数据。气泡的共振频率是一种直接测量 舱内压力的变化。这样的泡沫现在已经不存在了。技术 在第一阶段必须建立的创新是创造不溶解 气体微泡。这将通过形成气体胶束来实现。侯选人 将对胶束物质进行彻底检查。第二阶段的工作将是 旨在生产技术所需的精度和 延续早先由NHLBI支持的发展。这一概念 会在右心腔和右心腔产生压力时间历史 肺动脉。一旦知道了技术的雏形，就会变得更小 可以产生胶束，这些胶束可以穿过左心的肺 压力测量。潜在地，这种具有成本竞争力的概念可能 具有重要的商业价值，因为数以百万计的测量结果 每年都需要。

Management of various cardiac and pulmonary diseases is made exceedingly difficult by the lack of quantitative pressure and flow data. Reliable right heart pressures cannot be made noninvasively. The long term objective of the proposed activity is aimed specifically at noninvasive right heart pressure measurements. To accomplish this, tiny microbubbles will be injected and insonated ultrasonically upon entering the area where data are needed. The resonant frequency of the bubble is a direct measure of chamber pressure. Such bubbles do not now exist. The technological innovation that must be established in Phase I is to create nondissolving gas microbubbles. This will be done by forming gas micelles. Candidate micelle substances will be thoroughly examined. Phase II efforts will be directed at producing the precision needed for the technology and the continuation of the development supported earlier by NHLBI. The concept will produce pressure time histories in both right heart chambers and the pulmonary artery. Once the rudiments of the technology are known, smaller micelles could be produced which could traverse the lungs for left heart pressure measurements. Potentially, this cost competitive concept could have significant commercial value since many millions of measurements are required annually.